Citizens JMP Maintains a Buy Rating on BeOne Medicines (ONC)

Group 1 - BeOne Medicines Ltd. (NASDAQ:ONC) is recognized as a high growth international stock with a Buy rating and a price target of $348.00 set by Citizens JMP analyst Reni Benjamin [1] - The company announced positive topline results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL), achieving its primary endpoint of overall response rate (ORR) and demonstrating clinically meaningful responses in a rare B-cell lymphoma [2] - BeOne Medicines Ltd. is based in Switzerland and focuses on discovering and developing affordable, accessible, and innovative cancer treatments [3]